[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyadic International (DYAI)

Dyadic International (DYAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,877
  • Shares Outstanding, K 36,439
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -7,360 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.18
  • Price/Sales 8.50
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $-0.05 on 05/13/26
  • Next Earnings Date 08/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 749.61% (+749.61%)
  • Historical Volatility 45.62%
  • IV Percentile 84%
  • IV Rank 58.50%
  • IV High 1,199.56% on 02/12/26
  • IV Low 115.21% on 05/13/26
  • Expected Move (DTE 28) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 694
  • Open Int (30-Day) 735
  • Expected Range 0.7251 to 0.7251

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 1
  • High Estimate $-0.03
  • Low Estimate $-0.03
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6700 +8.96%
on 05/18/26
0.9310 -21.59%
on 04/23/26
-0.1065 (-12.73%)
since 04/21/26
3-Month
0.6546 +11.52%
on 03/26/26
1.0200 -28.43%
on 03/20/26
-0.0650 (-8.18%)
since 02/20/26
52-Week
0.6546 +11.52%
on 03/26/26
1.3460 -45.77%
on 10/01/25
-0.3000 (-29.13%)
since 05/21/25

Most Recent Stories

More News
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global...

DYAI : 0.7300 (-1.03%)
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals...

DYAI : 0.7300 (-1.03%)
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company...

DYAI : 0.7300 (-1.03%)
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales...

DYAI : 0.7300 (-1.03%)
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing...

DYAI : 0.7300 (-1.03%)
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company...

DYAI : 0.7300 (-1.03%)
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...

DYAI : 0.7300 (-1.03%)
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...

DYAI : 0.7300 (-1.03%)
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...

DYAI : 0.7300 (-1.03%)
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing...

DYAI : 0.7300 (-1.03%)

Business Summary

Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms...

See More

Key Turning Points

3rd Resistance Point 0.7749
2nd Resistance Point 0.7625
1st Resistance Point 0.7500
Last Price 0.7300
1st Support Level 0.7251
2nd Support Level 0.7127
3rd Support Level 0.7002

See More

52-Week High 1.3460
Fibonacci 61.8% 1.0819
Fibonacci 50% 1.0003
Fibonacci 38.2% 0.9187
Last Price 0.7300
52-Week Low 0.6546

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.